Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

This study found that nearly 40% of patients with severe alopecia areata who showed eyebrow or eyelash regrowth on baricitinib 4 mg achieved significant scalp hair regrowth by the second year of treatment.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

This study found that eyelash loss, facial papules, and body hair involvement were linked to severe frontal fibrosing alopecia, and antiandrogens were the most effective treatment.

This case report describes complete hair regrowth in a patient with alopecia universalis and improved psoriasis after treatment with the oral Janus kinase inhibitor, tofacitinib.

This study found that latanoprost induces significant growth and pigmentation of lashes and ancillary hairs, with effects mirroring both brief and chronic treatments observed in patients and animal models.

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.

This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.

This study observed that cyclosporine showed a trend toward improving alopecia areata symptoms compared to placebo, but the difference was not statistically significant.

This study described seven male patients and six female carriers of keratosis follicularis spinulosa decalvans, highlighting distinct dermatological and ophthalmic markers including follicular hyperkeratosis and corneal dystrophy.

This review discusses facial hair transplantation techniques for natural-appearing results in restoring eyebrows, beards, goatees, sideburns, and repairing alopecic scarring, reporting no new clinical results.

This review discusses adverse effects of cosmetic products and procedures on the ocular surface, including mild discomfort to severe vision-threatening conditions, and reports no new clinical results.

This source reports that bimatoprost, a medication approved for eyelash growth, has shown efficacy in treating eyebrow hypotrichosis, suggesting it as a noninvasive, effective, and well-tolerated option for enhancing eyebrow hair.

This report discusses the various causes and clinical assessment of madarosis, emphasizing the importance of recognizing and diagnosing associated vision or life-threatening conditions, without presenting new findings.

This letter to the editor discusses a potential link between new onset alopecia areata and SARS-CoV-2 infection, but reports no new clinical results.

This study reports that a clinical sequence can help eye care practitioners identify Demodex mites, which are often underdiagnosed and undertreated in ocular surface diseases.

This article reviews eyelash elongation as a side effect of EGFR inhibitors in cancer treatment, finding that the condition is typically not severe and may be managed by trimming.

This article discusses the role of interleukin-15 and Janus kinase inhibitors in alopecia areata based on a murine model and reports no new experimental results.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

This review discusses the cutaneous application of bimatoprost ophthalmic solution 0.03% for enhancing upper eyelash growth and suggests it is both safe and effective; no new clinical results are reported.

This case report found that topical bimatoprost usage in a female Hispanic patient with open-angle glaucoma was associated with hypertrichosis and increased pigmentation of vellus hairs on the malar region.

This study reports that periocular pigmentation may occur with the use of travoprost for treating alopecia areata of the eyelashes.

This study found that topical latanoprost was not effective in treating alopecia areata in eyebrows and eyelashes.

This review discusses the potential of prostaglandin analogs for hair growth and forms of alopecia, and reports no new clinical results.

This report from the National Registry of Drug-Induced Ocular Side Effects identifies 56 cases of alopecia associated with the use of topical ophthalmic β-blockers.

This article discusses the contributions of Dr. Shoji Okuda to the field of hair transplantation and reports no new research findings.